Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline? - sprookjes - yvandenbroek - TriplyDB

Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?

Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?

http://www.wikidata.org/entity/Q37506507

about

Pharmacological Alternatives for the Treatment of Neurodegenerative Disorders: Wasp and Bee Venoms and Their Components as New Neuroactive Tools Technology-aided leisure and communication: Opportunities for persons with advanced Parkinson's disease.Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditions Transplantation of Human Neural Stem Cells in a Parkinsonian Model Exerts Neuroprotection via Regulation of the Host Microenvironment Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.Rational drug discovery design approaches for treating Parkinson's disease.Editorial: Neurotherapeutics of movement disorders.Intrastriatal Transplantation of Human Neural Stem Cells Restores the Impaired Subventricular Zone in Parkinsonian Mice.Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression.Comparison of Three Extraction Approaches for the Isolation of Neurotransmitters from Rat Brain Samples.

P2860

Q26795786-5BA697E8-C911-4B1A-BE0E-A8573DF9A933 Q30373261-68407798-A51B-40C1-A103-D6F0E2CD2F04 Q36042479-5A833136-1555-4A1A-B82D-B98382B6B946 Q36324531-16C8D68A-C457-443A-A98C-446627347DCA Q36744366-2C6D3CFA-6BB1-4592-9E0C-04279CC98DF4 Q38520864-2D354206-2869-4F24-9A5F-1D20EF5F9A53 Q42736439-3CC8FB9C-5349-4DF5-8E7D-7A7DFCE3F9B4 Q48092963-335A8DB2-6DD3-4A47-A338-C426D95CF3B1 Q55132660-E8D00DA0-8FA5-460B-AF93-0F5393E7935B Q55642180-E023A54A-3314-4340-BE09-5849E39BA7FB

P2860

Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?

http://www.wikidata.org/entity/Q37506507

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?

@en

Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?

@nl

type

label

Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?

@en

Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?

@nl

prefLabel

Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?

@en

Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?

@nl

P1433

Q37506507-96D1AB26-3601-4389-A180-0E377E8722DC

P1476

Q37506507-06A759AC-1F7A-4457-9E9A-809B4688A847

P2093

Q37506507-372DA0A4-6101-4EF4-93AA-7A0DFBBD0499

P2860

Q37506507-00C9DBFE-6141-4CBE-986F-F65BB34774DF

Q37506507-00CFA208-2328-4C80-B66B-BCB189CD6209

Q37506507-01E53C68-BB19-4064-8938-450047432228

Q37506507-0370D26B-4D6B-4CC9-B182-5DD5B18DA265

Q37506507-04F87857-5C2B-4055-84C4-A703238181C5

Q37506507-06625BCA-75C0-4B54-8215-8350DC8547D0

Q37506507-08F4547D-1067-479F-BCF5-87F2F0F12060

Q37506507-0A19D595-5D43-49E7-8E8D-C3FC6FA8167F

Q37506507-0A3891CD-64AC-4A13-8454-17D72784B7F2

Q37506507-0D2DA380-61A7-4B41-A5C8-E3E09DAA1C34

P2888

Q37506507-24AEAE74-13F7-406F-B616-4DDC09CEE897

P304

Q37506507-A6807407-68DB-4DF6-BCBA-184CB41AE270

P31

Q37506507-5606A74D-5CC2-40C8-A10E-25D283CBCFA0

P356

Q37506507-07E27D45-0317-40E8-AAC6-81C17F8E5CAE

P433

Q37506507-536739D8-D8F7-4370-B21B-EAC559357A2E

P478

Q37506507-CCDC75BC-E2B3-423A-8D02-52D7051DED11

P50

Q37506507-09C07792-5AF5-43CD-953C-854C8870D019

P577

Q37506507-33920620-1BAD-4F0D-A74D-D606748D52C8

P698

Q37506507-BD6A5280-AC8A-43F8-83EF-90DAB947081F

P921

Q37506507-3FD22D83-4549-403B-BF9A-94396B0F8C80

Q37506507-50A36010-B879-48A9-862F-F00067997078

P932

Q37506507-DCA97033-6687-4483-9E80-BE97BD0A8C8A

P356

S13311-013-0239-9

P1433

Neurotherapeutics

P1476

Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?

@en

P2093

Albert Y Hung

http://www.w3.org/2001/XMLSchema#string

P2860

Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial

Staging of brain pathology related to sporadic Parkinson's disease

A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD

Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists

Serotonin receptors

Metabotropic glutamate receptors in the basal ganglia motor circuit

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial

Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification

The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease

Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease

P2888

s13311-013-0239-9

P304

34-46

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13311-013-0239-9

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Michael A Schwarzschild

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24310604

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3899482

http://www.w3.org/2001/XMLSchema#string